DOCSLIB.ORG

PREMARIN® Conjugated Estrogens Tablets Consumer Medicine Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PREMARIN® Conjugated Estrogens Tablets Consumer Medicine Information PREMARIN® Conjugated estrogens Tablets Consumer Medicine Information What is in this leaflet including for the prevention of PREMARIN is not suitable for birth osteoporosis, he or she will have control and it will not restore This leaflet answers some of the considered the benefits and risks of fertility. common questions about other treatments before prescribing This medicine is not expected to PREMARIN Tablets. It does not PREMARIN for you. affect your ability to drive a car or contain all of the available operate machinery. information. It does not take the How it works place of talking to your doctor or Menopause occurs naturally in pharmacist. All medicines have risks women, typically between the ages of and benefits. Your doctor has 45 and 55. During menopause, your Before you take weighed the risks of you taking body produces less estrogen than it PREMARIN PREMARIN against the benefits this did beforehand. This can cause medicine is expected to have for you. symptoms such as "hot flushes". When you must not take If you have any concerns about this Some women also have problems PREMARIN medicine, ask your doctor or with dryness of the vagina causing pharmacist. discomfort during or after sexual HRT should only be used if you intercourse. Some women develop have been fully informed of the Keep this leaflet with the medicine. osteoporosis during or after risks. You may need to read it again. menopause. This is a thinning of the The decision to use HRT should be bones making them weaker and more based on your particular needs and likely to break, especially the bones health, and made after a careful of the spine, hip and wrist. medical evaluation. What PREMARIN is Conjugated estrogens are like the used for Talk regularly with your doctor hormones produced by the ovaries about whether you still need before menopause. When given treatment with PREMARIN. PREMARIN is a type of treatment during or after menopause, they can called hormone replacement therapy Treatment with estrogens, with or help control the symptoms. (HRT) and contains the hormone without progestogens should be used estrogen in the form known as estrogen is used treat women who at the lowest effective dose and for conjugated estrogens. have had their uterus or "womb" the shortest period of time. removed. If you have not had your PREMARIN helps to relieve the Clinical trials have reported a slight uterus or "womb" removed, you will discomfort many women feel during increase in risk of ovarian cancer in need to take an estrogen with a women aged between 50-54 years and after menopause, including progestogen. symptoms such as "hot flushes", old when PREMARIN alone or in sweating and vaginal dryness. It Ask your doctor if you have any combination with a progestogen is helps to prevent thinning of the bones questions why PREMARIN has taken over 5 years. been prescribed for you. (osteoporosis), which can cause Do not take PREMARIN either fractures. Your doctor may have prescribed alone or with a progestogen to PREMARIN is also used to treat PREMARIN for another use. prevent heart attacks, stroke or women where either the ovary does This medicine is available only with dementia. not function properly or has been a doctor's prescription. Do not take PREMARIN if you removed. PREMARIN is not habit-forming. have an allergy, or think you have If your doctor thinks you will need to an allergy, to: take estrogens for a long time, PREMARIN 1 any medicine containing This medicine is not suitable for use kidney problems conjugated estrogens, the active in children. heart problems ingredient in PREMARIN Do not take PREMARIN if you are diabetes any of the ingredients listed at the breast feeding. migraine end of this leaflet Estrogens have been found in breast asthma any other similar medicines, such milk, and may reduce the production as other HRT medicines or oral of breast milk. epilepsy contraceptives ("birth control Do not take this medicine after the Lupus (systemic lupus pill"). expiry date (EXP) printed on the erythematosus) Some of the symptoms of an allergic pack or if the packaging is torn or hereditary angioedema (swelling reaction may include: shows signs of tampering. of the face, lips, tongue or throat shortness of breath If it is expired or damaged, return it that may cause difficulty wheezing or difficulty breathing to your pharmacist for disposal. swallowing or breathing) gall bladder disease swelling of the face, lips, tongue If you are not sure whether you or other parts of the body should start taking this medicine, a high level of blood fats talk to your doctor. rash, itching or hives on the skin. high or low levels of calcium in the blood Do not take PREMARIN if you Before you start to take have or have had any of the PREMARIN underactive thyroid gland following medical conditions: obesity. You must have a thorough medical breast cancer check-up before starting Tell your doctor if anyone in your endometrial or cervical cancer PREMARIN for the first time or if immediate family has had blood abnormal genital bleeding, which you are taking it again after a clots in the deep veins of the legs or blood vessels of lungs, a stroke or your doctor has not investigated break. heart attack. a problem with blood clots Tell your doctor if you are allergic to any foods, dyes preservatives or forming in your blood vessels, Taking Other Medicines such as painful inflammation of any other medicines. the veins (thrombophlebitis) or Tell your doctor if you have: Tell your doctor if you are taking birth control pills. the blockage of a blood vessel in a family history of breast cancer the legs (deep vein thrombosis or PREMARIN is not a contraceptive. nodules, lumps or cysts in your DVT), or lungs (pulmonary Since pregnancy may be possible breasts or any other benign breast embolism) early in the menopause, while you condition (not cancer) heart disease or stroke are still having menstrual periods, fibroids or other benign tumours you should ask your doctor about very high blood pressure that is of the uterus (not cancer) another (non-hormonal) method of not properly controlled unusual or irregular genital birth control. problems with your breasts that bleeding or spotting Tell your doctor or pharmacist if your doctor has not investigated endometriosis (material similar to you are taking any other medicines liver disease the uterine lining growing outside including: blood clotting problems. the uterus, causing pain or all prescription medicines bleeding) If you are not certain whether all medicines, vitamins, herbal these may apply to you, or you are high blood pressure supplements or natural therapies worried about anything in this list liver problems you buy without a prescription tell your doctor. from a pharmacy, supermarket, a condition called porphyria Do not take this medicine if you naturopath or health food shop. hearing difficulties are pregnant or think you are Some medicines may be affected by pregnant. yellowing of the whites of the PREMARIN or may affect how well Pregnancy must be excluded before eyes or skin (jaundice) during it works. You may need different pregnancy or when taking you take PREMARIN. amounts of your medicines, or you estrogen (e.g. birth control pill or may need to take different medicines. Do not give PREMARIN to a child. HRT) Your doctor will advise you. fluid retention PREMARIN 2 Tell your doctor or pharmacist if When to take PREMARIN If more than 12 hours has passed, you are taking any of the discard the missed tablet and take If you are not already using any type following: the next tablet when you normally of HRT you can start PREMARIN on would. herbal medicines containing St any convenient day. However, it is John's Wort recommended you start PREMARIN Do not take a double dose to make some medicines for epilepsy such after your last period. If you do not up for the one you missed. as phenytoin, phenobarbitone and have predictable periods, then start If you have trouble remembering carbamazepine PREMARIN on a Monday as this when to take your medicine, ask your some antibiotics and anti- matches the directions on the pharmacist for some hints. calendar pack. infectives such as rifampicin, erythromycin and clarithromycin If you are already using a different If you take too much type of HRT, your doctor can advise (Overdose) anti-fungal agents such as you when to start PREMARIN. ketoconazole and itraconazole Immediately telephone your doctor It does not matter if you take or the Poisons Information Centre thyroid replacement therapy PREMARIN before or after food. (telephone: 0800 POISON or 0800 corticosteroids, such as 764 766) or go to Accident and dexamethasone How much to take Emergency at the nearest hospital ritonavir for the treatment of HIV if you think you or anybody else For symptoms of menopause and infection has taken too much PREMARIN. prevention of osteoporosis, take one cyclosporin used to prevent organ tablet daily. Do this even if there are no signs of rejection. discomfort or poisoning. For women with a uterus, your Grapefruit juice may also affect how doctor will also prescribe a You may need urgent medical well PREMARIN works. progestogen tablet to be taken with attention. If you have not told your doctor your PREMARIN. For some women Symptoms of an overdose may about any of the above, tell them with a history of endometriosis, who include: have had a hysterectomy, a before you start taking feeling sick or vomiting PREMARIN. progestogen may also be needed. Your doctor will advise you. dizziness Your doctor and pharmacist have more information on medicines to be For women without fully-functioning feeling sleepy or tired careful with or avoid while you are ovaries, your doctor will prescribe breast tenderness PREMARIN according to your taking this medicine.
Load more

Recommended publications
  • PRESCRIBING INFORMATION OGEN* (Estropipate) Tablets 0.75 Mg, 1.5
    PRESCRIBING INFORMATION OGEN* (estropipate) Tablets 0.75 mg, 1.5 mg, 3.0 mg Estrogen Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway 25 May 2009 Kirkland, Quebec, H9J 2M5 Control No. 120830 * TM Pharmacia Enterprises S.A. Pfizer Canada Inc., licensee © Pfizer Canada Inc., 2009 OGEN* (estropipate) Prescribing Information Page 1 of 27 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS..................................................................................................11 CLINICAL TRIAL ADVERSE DRUG REACTIONS.....................................................13 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION..............................................................................15 OVERDOSAGE ................................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY ............................................................16
    [Show full text]
  • Bazedoxifene–Conjugated Estrogens for Treating Endometriosis Endometriosis: Nina S
    Endometriosis: Case Report Bazedoxifene–Conjugated Estrogens Teaching Points for Treating Endometriosis 1. The estrogen receptor (ER) is a definitive down- stream target in endometriosis. As an endometrial ER antagonist, bazedoxifene assures not only block- Valerie A. Flores, MD, ade of estrogen binding, but it also has the ability to Nina S. Stachenfeld, PhD, degrade the receptor. This unique property of baze- and Hugh S. Taylor, MD doxifene blocks estrogen action and makes it an attractive treatment option for endometriosis. 2. Conjugated estrogens paired with bazedoxifene do BACKGROUND: Endometriosis is a gynecologic disorder not require a progestin to block endometrial affecting 6–10% of reproductive-aged women. First-line growth, thus avoiding the side effects associated therapies are progestin-based regimens; however, failure with progestin-based regimens. 08/19/2018 on BhDMf5ePHKbH4TTImqenVGLGjjqParD6K7Nl5tTGGFqgjMmLRmuIlIgbkUbgVXoQ by http://journals.lww.com/greenjournal from Downloaded rates are high, often requiring alternative hormonal agents, each with unfavorable side effects. Bazedoxifene with con- ’ 1 Downloaded that can have a significant effect on patients lives. jugated estrogens is approved for treatment of menopausal Treatment consists of agents that induce atrophy of symptoms, and use in animal studies has demonstrated from regression of endometriotic lesions. As such, it represents endometriotic lesions. There is tremendous need for http://journals.lww.com/greenjournal a potential treatment option for endometriosis. therapies that are effective, have favorable side effect profiles, and can be used long term in women with CASE: A patient with stage III endometriosis referred for symptomatic endometriosis, especially for those not management of dysmenorrhea and cyclic pelvic pain was treated with 20 mg bazedoxifene and 0.45 mg conjugated responding to progestin-based regimens.
    [Show full text]
  • Estrogen Agents, Oral-Transdermal
    GEORGIA MEDICAID FEE-FOR-SERVICE ESTROGEN AGENTS, ORAL - TRANSDERMAL PA SUMMARY Preferred Non-Preferred Oral Estrogens Estradiol generic n/a Menest (esterified estrogens) Premarin (estrogens, conjugated) Oral Estrogen/Progestin Combinations Angeliq (drospirenone/estradiol) Bijuva (estradiol/progesterone) Estradiol/norethindrone and all generics for Activella Norethindrone/ethinyl estradiol and all generics for Femhrt Low Dose 0.5/2.5 (norethindrone/ethinyl Femhrt Low Dose estradiol) Jinteli and all generics for Femhrt 1/5 (norethindrone/ethinyl estradiol) Prefest (estradiol/norgestimate) Premphase (conjugated estrogens/medroxyprogesterone) Prempro (conjugated estrogens/medroxyprogesterone) Topical Estrogens Alora (estradiol transdermal patch) Divigel (estradiol topical gel) Estradiol transdermal patch (generic Climara) Elestrin (estradiol topical gel) Evamist (estradiol topical spray solution) Estradiol transdermal patch (generic Vivelle-Dot) Menostar (estradiol transdermal patch) Minivelle (estradiol transdermal patch) Vivelle-Dot (estradiol transdermal patch) Topical Estrogens/Progestin Combination Climara Pro (estradiol/levonorgestrel transdermal patch) n/a Combipatch (estradiol/norethindrone transdermal patch) Oral Selective Estrogen Receptor Modulator (SERMs) Raloxifene generic Duavee (conjugated estrogens/bazedoxifene) Osphena (ospemifene) LENGTH OF AUTHORIZATION: 1 year PA CRITERIA: Bijuva ❖ Approvable for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects to at least two preferred oral estrogen/progestin combination products. Revised 6/29/2020 Norethindrone/Ethinyl Estradiol and All Generics for Femhrt Low Dose ❖ Prescriber must submit a written letter of medical necessity stating the reasons at least two preferred oral estrogen/progestin combination products, one of which must be brand Femhrt Low Dose, are not appropriate for the member.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • AMS the Role of Serms After Menopause
    Information Sheet The Role of SERMs after Menopause SERMs is the shorthand term for a class of drug called selective oestrogen receptor modulators. These compounds are also referred to as oestrogen agonist/antagonists. They are a versatile group of drugs that can be used to treat a number of conditions associated with aging such as osteoporosis and hormone responsive cancers, and also infertility. Different kinds of SERMS • Naturally occurring SERMs include plant-derived oestrogens or phyto-oestrogens that are sometimes used to treat symptoms of menopause. • Clomiphene citrate is an early SERM which is used to induce ovulation in women desiring pregnancy. • Tamoxifen is another SERM which is taken to reduce the risk of recurrent breast cancer and to prevent the development of breast cancer in women at increased risk of breast cancer. It acts as an anti-oestrogen to reduce oestrogen stimulation in the breast but as an oestrogen agonist in other parts of the body. It improves bone density but increases the risk of endometrial cancer and also of deep vein thrombosis (DVT). In women who have had breast cancer this risk is outweighed by the benefits of reduction in risk of recurrent breast cancer. • Newer SERMs are being developed to make use of the positive effects of oestrogen such as preventing osteoporosis, treating genital atrophy (vaginal dryness), reducing cardiovascular risk and preventing breast cancer, These agents aim to minimise the negative effects of the older agents. Raloxifene,is already available in both Australia and New Zealand. Bazedoxifene and ospemifene are available in the USA and in some parts of Europe.
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
    Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Print Your Doctor Discussion Guide
    Doctor Discussion Guide What to Ask What& toTell Talking about painful intercourse due to menopause with your doctor. What matters most when speaking with your doctor is STARTING THE CONVERSATION that you are comfortable communicating your needs. Consider the following approaches: • The Direct Approach: “Since menopause, intercourse has been painful. What can I do?” • The Unwelcome Surprise: “You know, I expected hot flashes and night sweats. I never expected pain during intercourse. What can I do?” • The Show-Me: “There’s something else that’s been bothering me. I’d like you to take a look at this.” Then hand your doctor this guide. Asking the right questions is the quickest way WHAT TO ASK to get the information you need. • Is Premarin Vaginal Cream right for my situation? - What are the possible side effects? - How is it used? - How long would I need to use it? INDICATIONS Premarin (conjugated estrogens) Vaginal Cream is used after menopause to treat menopausal changes in and around the vagina and to treat moderate to severe painful intercourse caused by these changes. Each gram contains 0.625 mg conjugated estrogens, USP. IMPORTANT SAFETY INFORMATION (continued on following page) Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Premarin (conjugated estrogens) Vaginal Cream. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. Do not use estrogens, with or without progestins, to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
    [Show full text]
  • "Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms
    STEPS New Drug Reviews Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms KRISTINA JOHNSON, MD, and FERN HAUCK, MD, MS, University of Virginia Department of Family Medicine, Charlottesville, Virginia STEPS new drug reviews Conjugated estrogens/bazedoxifene (Duavee) combines conjugated estrogen with bazedoxi- cover Safety, Tolerability, fene, a selective estrogen receptor modulator. Bazedoxifene stimulates estrogen receptors in Effectiveness, Price, and 1 Simplicity. Each indepen- bone and has antagonistic effects in the breast and uterus. Conjugated estrogens/bazedoxi- dent review is provided fene is labeled for the treatment of moderate to severe vasomotor symptoms associated with by authors who have no menopause and prevention of postmenopausal osteoporosis.2 financial association with the drug manufacturer. This series is coordinated Drug Dosage Dose form Cost* by Allen F. Shaughnessy, PharmD, MMedEd, Con- Conjugated estrogens/ 0.45 mg/20 mg 0.45-mg/20-mg $145 tributing Editor. bazedoxifene (Duavee) once daily tablet A collection of STEPS pub- *—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com lished in AFP is available (accessed December 14, 2015). at http://www.aafp.org/ afp/steps. SAFETY TOLERABILITY As with other estrogen therapies, conjugated Conjugated estrogens/bazedoxifene is gener- estrogens/bazedoxifene includes a boxed warn- ally well tolerated. About one in 12 patients ing of increased risk of dementia in women older (8%) will stop taking the medication in than 65 years, endometrial cancer, stroke, and the first year because of adverse effects.4,5 deep venous thrombosis.2 However, in stud- When compared with conjugated estrogens/ ies of 7,487 patients, there was no increase in medroxyprogesterone, conjugated estrogens/ endometrial hyperplasia.
    [Show full text]
  • DUAVEE® (Conjugated Estrogens-Bazedoxifene) Oral Tablet
    PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/17/2016 SECTION: DRUGS LAST REVIEW DATE: 11/19/2020 LAST CRITERIA REVISION DATE: 11/19/2020 ARCHIVE DATE: DUAVEE® (conjugated estrogens-bazedoxifene) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.
    [Show full text]
  • Conjugated Estrogens/Bazedoxifene (Duavee)
    Clinical Policy: Conjugated Estrogens/Bazedoxifene (Duavee) Reference Number: HIM.PA.140 Effective Date: 10.24.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Conjugated estrogens/bazedoxifene (Duavee®) is a combination of conjugated equine estrogens and an estrogen agonist/antagonist. The pairing of conjugated estrogens with bazedoxifene produces a composite effect that is specific to each target tissue. The bazedoxifene component reduces the risk of endometrial hyperplasia that can occur with the conjugated estrogens component. FDA Approved Indication(s) Duavee is indicated for the treatment of the following conditions in women with a uterus: • Treatment of moderate-to-severe vasomotor symptoms associated with menopause • Prevention of postmenopausal osteoporosis Limitation(s) of use: • Duavee should be used for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. • When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria I. Initial Approval Criteria A. Vasomotor Symptoms (must meet all): 1. Diagnosis of vasomotor symptoms associated with menopause; 2. Member has not undergone a hysterectomy; 3. Failure of 2 formulary estrogen products (not contraceptives) unless contraindicated or clinically significant adverse effects are experienced; 4.
    [Show full text]